Immunocore nabs US$40m from Gates Foundati...British T cell receptor specialist Immunocore Ltd will receive a US$40m investment from the the Bill & Melinda Gates Foundation to develop immunotherapies that fight tuberculosis and HIV. … more ➔
CHMP candidate checkThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) published the results of its September meeting. more ➔
EMA rejects Santhera’s DMD drug The European Medicine Agency’s CHMP has rejected a type II extension application to Santhera Pharmaceutical’s coenzyme Q10 analogon idebenone (Raxone) as treatment for patients with Duchenne muscular … more ➔
Sophia Genetics raises US$30mArtificial intelligence (AI) specialist Sophia Genetics SA (St. Sulpice, Switzerland) raised US$30m in a series D round to foster global expansion of its cancer diagnostics annotation platform SOPHiA … more ➔
MS: Gut microbobes drive inflammationTwo research team independently report they have identified specific microbes in the gut of mice and of treatment-naive patients with multiple sclerosis (MS) regulating immune responses. Phase I trails … more ➔
Life Sciences majors expand digital cancer... Thermo Fisher Scientific has extended its Next Generation Sequencing Companion Dx Center of Excellence Programme (COEP) in Europe. The next-generation sequencing (NGS) provider added a second agreement … more ➔
Nova challenges EU’s tank or table... A comprehensive sustainability assessment carried out by nova-Institute shows that first and second generation bioethanol is feasible for the EU’s climate strategy. The study challenges the politically … more ➔
Immunooncology: Roche presents blood bioma...Roche is trying to offer a solution for patient selection in immunooncology. At the ESMO congress in Madrid, the theranostics company presented a liquid biopsy test that measures the tumour mutational … more ➔
‘Adrenaline’ of the immune sys... Portuguese and Swiss scientists have discovered that neurons located at mucosal tissues can immediately detect an infection in the organism, promptly producing a substance that acts as an "adrenaline … more ➔
AMAL Therapeutics raises €8mSwiss cancer vaccine developer AMAL Therapeutics has raised €8m in a Series B round led by existing investor Boehringer Ingelheim Venture Fund, and new investors BioMedPartners and Helsinn Investment … more ➔
